Oppenheimer raises Ligand Pharmaceuticals target price to $346 from $334
LGND•Oppenheimer raised its target price for Ligand Pharmaceuticals to $346 from $334.
Related News
LKQ Corp: Raymond James cuts target price to $25 from $30
LKQ•
Hongli Group in talks to acquire 20% stake in Xell Energy
HLP•
Spot silver drops below $50/oz for the first time since November 2025
GLD•
Bristol-Myers Squibb announces availability of Form 10-Q for period ended Sept. 30, 2026
BMY•
US labor costs rise moderately in third quarter
SPY•